InnoCare Pharma (FRA:33C) Buildings And Improvements : €60.43 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Buildings And Improvements?

InnoCare Pharma's quarterly buildings and improvements declined from Jun. 2023 (€6.42 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€60.43 Mil).

InnoCare Pharma's annual buildings and improvements increased from Dec. 2021 (€20.90 Mil) to Dec. 2022 (€42.26 Mil) and increased from Dec. 2022 (€42.26 Mil) to Dec. 2023 (€60.43 Mil).

InnoCare Pharma Buildings And Improvements Historical Data

The historical data trend for InnoCare Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Buildings And Improvements Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

1.28

2.89

20.90

42.26

60.43

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial												42.26	6.42	-	60.43	-

InnoCare Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines